| |
No. of Pts
|
Pre-SUV *
|
Post-SUV *
|
ΔSUV% *
|
HPR (%)
|
|---|
|
ER
| | | | | |
|
Positive
|
38
|
6.4 ± 3.3
|
3.7 ± 2.1
|
30 ± 57
|
3 (7.9)
|
|
Negative
|
40
|
8.6 ± 4.9
|
4.1 ± 3.1
|
48 ± 37
|
11 (27.5)
|
| | |
P = 0.047
|
P = 0.936
|
P = 0.038
|
P = 0.037†
|
|
PR
| | | | | |
|
Positive
|
30
|
6.5 ± 3.3
|
3.5 ± 2.4
|
36 ± 63
|
3 (10.0)
|
|
Negative
|
48
|
8.2 ± 4.8
|
4.2 ± 2.8
|
42 ± 37
|
11 (22.9)
|
| | |
P = 0.187
|
P = 0.347
|
P = 0.837
|
P = 0.226†
|
|
HER2
| | | | | |
|
Positive
|
17
|
6.8 ± 3.2
|
3.2 ± 2.6
|
51 ± 36
|
5 (29.4%)
|
|
Negative
|
61
|
7.7 ± 4.6
|
4.1 ± 2.7
|
36 ± 51
|
9 (14.8%)
|
| | |
P = 0.818
|
P = 0.247
|
P = 0.189
|
P = 0.164†
|
|
Triple negativity
| | | | | |
|
TNBC
|
26
|
9.8 ± 5.3
|
5.0 ± 3.0
|
42 ± 35
|
6 (23.1)
|
|
Non-TNBC
|
52
|
6.4 ± 3.2
|
3.4 ± 2.3
|
38 ± 54
|
8 (15.4)
|
| | |
P = 0.008
|
P = 0.076
|
P = 0.799
|
P = 0.404†
|
|
Molecular phenotype
| | | | | |
|
Luminal A/B
|
40
|
6.3 ± 3.3
|
3.6 ± 2.2
|
33 ± 57
|
3 (7.5)
|
|
HER2
|
12
|
6.6 ± 3.2
|
2.8 ± 2.6
|
56 ± 39
|
5 (41.7)
|
|
TNBC
|
26
|
9.8 ± 5.3
|
5.0 ± 3.0
|
42 ± 35
|
6 (23.1)
|
| | |
P = 0.016‡
|
P = 0.055‡
|
P = 0.150‡
|
P = 0.018†
|
|
Ki-67
| | | | | |
|
Low expression§
|
30
|
6.2 ± 4.1
|
3.6 ± 2.6
|
27 ± 65
|
4 (13.3)
|
|
High expression
|
41
|
8.5 ± 4.4
|
4.0 ± 2.8
|
49 ± 33
|
10 (24.4)
|
| | |
P = 0.018
|
P = 0.541
|
P = 0.052
|
P = 0.367†
|
- HPR, histopathologic responder; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.
- * Data are presented as the mean ± standard deviation.
-
† P-values are based on Chi square or Fisher's exact test.
-
‡ P-values are based on Kruskal-Wallis test, otherwise P-values are based on Mann-Whitney U test, presuming to be non-parametric statistics.
-
§ Low expression of Ki-67 was defined as ≤ 5%, and 7 patients were not available for Ki-67 results.
